Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
IJSREM66684
Volume:
10 |
8 |
Aug 2026
Pages:
1-20
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
Pharmacy
Bharat Institute Of Pharmacy, India
Pharmacy
Bharat Institute Of Pharmacy, India
Pharmacy
Bharat Institute Of Pharmacy, India
Pharmacy
Bharat Institute Of Pharmacy, India
Pharmacy
Bharat Institute Of Pharmacy, India
Pharmacy
Bharat Institute Of Pharmacy, India
Breast cancer remains one of the leading causes of cancer-related morbidity and mortality among women worldwide despite significant advances in diagnosis and treatment. Conventional chemotherapeutic approaches often suffer from poor selectivity, systemic toxicity, and the development of drug resistance, highlighting the need for safer and more effective therapeutic strategies. Naringenin, a naturally occurring flavonoid, has demonstrated promising anticancer, antioxidant, and anti-inflammatory activities; however, its clinical application is restricted by poor aqueous solubility and limited oral bioavailability. The present study focuses on the development and optimization of naringenin-loaded phytosomal nanoparticles to improve its physicochemical properties and therapeutic potential for breast cancer management. Phytosomes were prepared using the thin-film hydration technique and subsequently converted into nanoparticles through the nanoprecipitation method. A Box–Behnken experimental design was employed to optimize critical formulation variables and evaluate their influence on key quality attributes, including particle size, polydispersity index, zeta potential, entrapment efficiency, drug loading, and drug release behavior. The optimized formulation was further characterized using FTIR, DSC, XRD, SEM, and TEM to assess molecular compatibility, thermal characteristics, crystallinity, and surface morphology. In vitro drug release and stability studies were also performed to determine formulation performance and storage stability. The optimized phytosomal nanoparticles are expected to provide improved drug encapsulation, sustained drug release, enhanced stability, and superior bioavailability compared with conventional naringenin formulations. This nanocarrier-based approach may represent a promising strategy for targeted breast cancer therapy and offers a potential platform for improving the clinical effectiveness of plant-derived bioactive compounds.
KEYWORDS
The present study successfully developed naringenin-loaded phytosomal nanoparticles using a combination of phytosomal and nanoparticle technologies. Optimization through the Box–Behnken Design enabled the selection of an optimum formulation with desirable particle size, high entrapment efficiency, and improved formulation stability. The optimized nanoparticles exhibited enhanced physicochemical characteristics and a sustained drug release profile, which may improve the bioavailability and therapeutic performance of naringenin. Overall, the developed formulation demonstrates promising potential as an efficient nanocarrier for targeted breast cancer therapy. Further in vitro and in vivo studies are recommended to confirm its safety and therapeutic efficacy before clinical application.
[1] Sung, H., Filho, A. M., Laversanne, M., Ferlay, J., Siegel, R. L., Soerjomataram, I., Jemal, A., & Bray, F. (2026). Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: a cancer journal for clinicians, 76(4), e70090. https://doi.org/10.3322/caac.70090 [2] DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer; 2023. [3] Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: current advances and future directions. International journal of medical sciences, 9(3), 193–199. https://doi.org/10.7150/ijms.3635 [4] Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575(7782), 299–309. https://doi.org/10.1038/s41586-019-1730-1 [5] Salehi, B., Fokou, P. V. T., Sharifi-Rad, M., Zucca, P., Pezzani, R., Martins, N., & Sharifi-Rad, J. (2019). The Therapeutic Potential of Naringenin: A Review of Clinical Trials. Pharmaceuticals (Basel, Switzerland), 12(1), 11. https://doi.org/10.3390/ph12010011 [6] Stabrauskiene, J., Kopustinskiene, D. M., Lazauskas, R., & Bernatoniene, J. (2022). Naringin and Naringenin: Their Mechanisms of Action and the Potential Anticancer Activities. Biomedicines, 10(7), 1686. https://doi.org/10.3390/biomedicines10071686 [7] P, K., & R, K. (2024). Phytosome Technology: A Novel Breakthrough for the Health Challenges. Cureus, 16(8), e68180. https://doi.org/10.7759/cureus.68180 [8] Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature reviews. Drug discovery, 20(2), 101–124. https://doi.org/10.1038/s41573-020-0090-8 [9] Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nature reviews. Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108 [10] Hayes S. (2014). Remington: The Science and Practice of Pharmacy, volume I and volume II. Twenty-second edition. Journal of the Medical Library Association: JMLA, 102(3), 220–221. https://doi.org/10.3163/1536-5050.102.3.016
Publication Date
8/11/2026
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
2
Total views since publication
PDF Downloads
6
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...